Elanco Animal Health Acquires Boehringer Ingelheim Vetmedica’s U.S. Feline, Canine and Rabies Vaccines Portfolio

January 03, 2017

NEW YORK – Paul Hastings LLP, a leading global law firm, announced today that the firm represented Elanco US Inc., a division of Eli Lilly and Company, in the completion of its approximately $885 million acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio, along with a fully integrated manufacturing and R&D site and several pipeline assets.

The acquisition diversifies Elanco’s U.S. companion animal portfolio by adding vaccines for a range of common concerns, including bordetella, Lyme disease, feline leukemia, rabies, and parvovirus.

The Paul Hastings team was led by Mergers and Acquisitions partner

, and included associates , , , , , , and from the Mergers and Acquisitions practice. The Paul Hastings team also included partners and and associates and , who advised on Intellectual Property matters; partner, , who advised on Environmental matters; partner and associate , who advised on Real Estate matters; partner and associate , who advised on Tax matters; and partner , who advised on Employment and Benefits matters. Partner also advised on the transaction.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.

Practice Areas



Submission Requests
Corporate, Litigation, Real Estate, and Tax
Scott Wasserman
Intellectual Property, Life Sciences, and Employment
Becca Hatton
Katy Foster

Get In Touch With Us

Contact Us